There are currently 23 clinical trials in Murfreesboro, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including International Clinical Research - Tennessee LLC, Tennessee Oncology, PLLC and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Local Institution - 007-928-F, Murfreesboro, Tennessee
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Recruiting
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
06/26/2025
Locations: International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Conditions: NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/26/2025
Locations: Sl0044 50693, Murfreesboro, Tennessee
Conditions: Systemic Lupus Erythematosus
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Recruiting
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Investigative Site US043, Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/26/2025
Locations: International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Conditions: Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/26/2025
Locations: International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Conditions: Prurigo Nodularis
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/25/2025
Locations: International Clinical Research - Tennessee (IC Research), Murfreesboro, Tennessee
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/25/2025
Locations: Investigative Site US005, Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
Recruiting
Primary Objective: To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity. Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient reported outcomes (PROs) in participants with SS. 2. To evaluate the safety and tolerability of dazodalibep in participants with SS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Murfreesboro Medical Clinic Westlawn, Murfreesboro, Tennessee
Conditions: Sjogren's Syndrome
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Recruiting
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Site Number - 1029, Murfreesboro, Tennessee
Conditions: Rheumatoid Arthritis
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Recruiting
This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated participants with moderate to severe atopic dermatitis (AD) who have previously been enrolled in an amlitelimab clinical trial. All participants will have visits during the treatment period every 4 weeks. Responder participants... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/24/2025
Locations: International Clinical Research - Tennessee- Site Number : 8401008, Murfreesboro, Tennessee
Conditions: Dermatitis Atopic
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Investigative Site US232, Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa (HS)